Data on clinical studies in MTC are scarce, but in a single phase 1 study including a patient with MTC, blocking the PD-1/PD-L1 interaction using nivolumab, an anti-PD-1 agent, resulted in a partial response (Yamamoto et al. 2017). The gene discussed is CD274; the disease is medullary thyroid gland carcinoma.